Opioids are compounds
Opioids are medications that relieve pain by reducing the intensity of the pain signals reaching the brain. Opioids are a type of narcotic medication and can have serious side effects if not used as prescribed or used incorrectly. Although opioids are very effective for treating and managing pain, their frequent use results in global opioid-induced constipation (OIC)market. Opioids bind themselves to mu opioid receptors present in the intestines and hence, patients taking opioids suffer from chronic and severe constipations, affecting the lifestyle of a patient.
Get Free Sample Research Report:
Usage of Opioids to Treat Chronic Cancer Pain Boosts Opioid-induced Constipation Treatment Market
Cancer is one of the most prevalent diseases in the world today, affecting people in all age groups. Currently, opioids are widely used for treating chronic cancer pain and non-cancerous pain in Europe, North America, and Australia. Opioids have found high acceptance in these regions and, as a result, there has been an increase in the number of patients suffering from opioid-induced constipation. Rising healthcare costs have also proven to be beneficial for the opioid-induced constipation treatment market.
The opioid-induced constipation treatment market benefits greatly as traditional laxatives are facing various legal hurdles for the treatment of opioid-induced constipation. The opioid-induced constipation treatment market is also driven by the low cost of this therapy and ease of access to these medicines.
Mu-opioid Receptor Antagonist was the Fastest Growing Segment in 2014
The global opioid-induced constipation treatment market is segmented on the basis of drug class into mu-opioid receptor antagonists, chloride channel activators, and others. Due to the early approval and launch of Amitiza, the chloride channel activators segment accounted for the largest share in the opioid induced constipation treatment market in 2014. Mu-opioid receptor antagonists were the fastest growing segment due to the recent launch of a new drug called Moventik. The strong presence of pipeline drugs has also boosted the market for opioid receptor antagonists.
Based on dosage form, the global opioid-induced constipation treatment market is segmented into solid, semi-solid, and liquid. The solid treatment segment dominated the market and is expected to retain its dominance in the coming years. The growth can be attributed to the launch of new drugs in solid form such as capsules, pills, and tablets. High patient compliance is also one of the reasons for the dominance of solid opioid-induced constipation treatment. The liquid and semi-solid dosage markets held relatively smaller shares in the global opioid-induced constipation treatment market.
AstraZeneca and Daiichi Sankyo Sign a Co-commercialization Agreement for Moventik
The major players in the global opioid-induced constipation treatment market include Takeda Pharmaceutical Company Limited, Bayer AG, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, C.B. Fleet Company, Inc., Daewoong Co. Ltd., AstraZeneca plc, Boehringer Ingelheim GmbH, and Cosmo Pharmaceuticals.
Major acquisitions and collaborations among these companies to commercialize opioid-induced constipation treatment medicines, such as the signing of a co-commercialization agreement for Moventik by AstraZeneca and Daiichi Sankyo, and the entrance of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioids-induced constipation treatment market in the coming years.
Full Research Report on Global Opioid Induced Constipation Treatment Market:
website of Opioid-induced Constipation Treatment Market Expected as Traditional Laxatives Face Legal